US FDA's Abram Makes The Case For 180-Day Exclusivity Reform
Proposed trigger changes will discourage low-quality applications, not disincentivize patent challenges, deputy commissioner suggests at generic association's annual meeting.
You may also be interested in...
To help with the transition to Biden’s COVID-19 response, Woodcock will retain some therapeutic development duties in the program the Trump administration had called Operation Warp Speed.
Where can HHS go it alone, and where does it need Congress?
US FDA softens its tone on idea and encourages industry to voice its (predominantly negative) opinion publicly.